Evidence map›Paper›PMID 30227174›Full record

ArticleRegulatory toxicology and pharmacology : RTP2018

In vitro test systems to determine tetracycline residue binding to human feces.

Youngbeom Ahn, Ji Young Jung, Brian T Veach, Sangeeta Khare, Kuppan Gokulan, Silvia A Piñeiro, Carl E Cerniglia

Open access · greenAbstract read
In one paragraph

Article in Regulatory toxicology and pharmacology : RTP, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Youngbeom AhnDivision of Microbiology, National Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, AR, USA. Electronic address: young.ahn@fda.hhs.gov.
Ji Young JungDivision of Microbiology, National Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, AR, USA.
Brian T VeachArkansas Regional Laboratory, Office of Regulatory Affairs, U.S. Food and Drug Administration, Jefferson, AR, USA.
Sangeeta KhareDivision of Microbiology, National Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, AR, USA.
Kuppan GokulanDivision of Microbiology, National Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, AR, USA.
Silvia A PiñeiroDivision of Human Food Safety, Center for Veterinary Medicine, U.S. Food and Drug Administration, Rockville, MD, USA.
Carl E CernigliaDivision of Microbiology, National Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, AR, USA.
National Center for Toxicological Research · USCenter for Veterinary Medicine · USUnited States Food and Drug Administration · US

Funding

Intramural FDA HHS FD999999
6 · The paper itself

Abstract

The use of antimicrobials, such as tetracycline, in food-producing animals may result in antimicrobial drug residues (ADR) in edible tissues from treated animals and contribute to the emergence of antibiotic resistant bacteria. The Veterinary International Conference on Harmonization (VICH) document (VICH GL36(R)/FDA-CVM Guidance for Industry#159) provides guidance on evaluating the safety of veterinary ADR in the human foods as related to effects on the human intestinal microbiome. One recognized research gap is a need for additional data and testing requirements to determine the fraction of an oral dose of ADR available to intestinal microorganisms. In the present study, we address this need by examining the binding of tetracycline to human feces using chemical and microbiological assays. High-performance liquid chromatography and liquid chromatography mass spectrometry assays showed that 25% (w/v) diluted steam sterilized feces dosed with 0.15 and 1.5 μg/ml tetracycline had binding of 58.2 ± 10.8% and 56.9 ± 9.1%, respectively. Tetracycline binding to fecal slurries gave similar results. Microbiological assays with two reference bacterial strains validated the results of the chemical assays. Based on data from chemical and microbiological assays methods, the fraction of dose available to microorganisms was 0.418 and 0.431 of the 0.15 and 1.5 μg/ml tetracycline treatments, respectively. This study also proposes factors to be considered when designing and conducting experiments to determine the percent of an antimicrobial agents that is available to microorganisms in the gastrointestinal tract.

Indexed as

AnimalsAnti-Bacterial AgentsBacteriaDrug Resistance, BacterialFecesFood ContaminationGastrointestinal MicrobiomeGastrointestinal TractHumansTetracyclineAnti-Bacterial AgentsTetracyclineBindingHuman fecal slurriesIn vitro test systemsTetracycline

Identifiers

PMID30227174
PMCPMC12423784
OpenAlexW2890632955

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.